The agreement also covers Vitro Biopharma adult mesenchymal stem cell (MSC) lines and derivatives, MSC-Gro(TM) and LUMENESC(TM).
Vitro Biopharma president and CEO Jim Musick said Vitro is pleased to announce its distribution agreement with StemGenesis.
”I met with StemGenesis at the annual ISCT meeting held in Seattle, WA in June of this year and we have mutual interest in serving the needs of the stem cell industry through the development, manufacture and distribution of high-quality medical devices serving specific needs within stem cell research and clinical development," Musick added.
StemGenesis CEO said the current market demand in China for the advanced stem cell products and technologies is developing too fast to be met.
”We believe Vitro Biopharma’s products, especially its stem cell culture media and assays, will offer high quality products with unique features for our Chinese customers," StemGenesis CEO added.